JP2002541214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541214A5 JP2002541214A5 JP2000610512A JP2000610512A JP2002541214A5 JP 2002541214 A5 JP2002541214 A5 JP 2002541214A5 JP 2000610512 A JP2000610512 A JP 2000610512A JP 2000610512 A JP2000610512 A JP 2000610512A JP 2002541214 A5 JP2002541214 A5 JP 2002541214A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- compounds
- composition according
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 42
- 239000008194 pharmaceutical composition Substances 0.000 description 33
- 102100039663 Receptor-type tyrosine-protein phosphatase F Human genes 0.000 description 28
- 238000000034 method Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 24
- 201000010099 disease Diseases 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 11
- 230000010393 epithelial cell migration Effects 0.000 description 10
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 102000015735 Beta-catenin Human genes 0.000 description 7
- 108060000903 Beta-catenin Proteins 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000054078 gamma Catenin Human genes 0.000 description 2
- 108010084448 gamma Catenin Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12867399P | 1999-04-09 | 1999-04-09 | |
| US60/128,673 | 1999-04-09 | ||
| PCT/US2000/009274 WO2000061180A2 (en) | 1999-04-09 | 2000-04-06 | Products and methods for treating ptp lar related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541214A JP2002541214A (ja) | 2002-12-03 |
| JP2002541214A5 true JP2002541214A5 (https=) | 2007-06-14 |
Family
ID=22436431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000610512A Pending JP2002541214A (ja) | 1999-04-09 | 2000-04-06 | Ｐｔｐ ｌａｒ関連疾病の治療のための物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090074722A1 (https=) |
| EP (1) | EP1169054B1 (https=) |
| JP (1) | JP2002541214A (https=) |
| AT (1) | ATE272406T1 (https=) |
| AU (1) | AU4210900A (https=) |
| CA (1) | CA2365945A1 (https=) |
| DE (1) | DE60012718T2 (https=) |
| PT (1) | PT1169054E (https=) |
| WO (1) | WO2000061180A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006040322A1 (en) * | 2004-10-12 | 2006-04-20 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040629A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
| JP4713698B2 (ja) * | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| WO1999046237A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
-
2000
- 2000-04-06 WO PCT/US2000/009274 patent/WO2000061180A2/en not_active Ceased
- 2000-04-06 DE DE60012718T patent/DE60012718T2/de not_active Expired - Fee Related
- 2000-04-06 EP EP00921845A patent/EP1169054B1/en not_active Expired - Lifetime
- 2000-04-06 AT AT00921845T patent/ATE272406T1/de not_active IP Right Cessation
- 2000-04-06 CA CA002365945A patent/CA2365945A1/en not_active Abandoned
- 2000-04-06 AU AU42109/00A patent/AU4210900A/en not_active Abandoned
- 2000-04-06 PT PT00921845T patent/PT1169054E/pt unknown
- 2000-04-06 JP JP2000610512A patent/JP2002541214A/ja active Pending
-
2008
- 2008-02-26 US US12/071,815 patent/US20090074722A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102074528B1 (ko) | 뉴클레오티드를 함유하는 뉴클레오솜의 검출 방법 | |
| KR102130855B1 (ko) | 히스톤 변이체를 함유하는 뉴클레오솜의 검출 방법 | |
| JP6581247B2 (ja) | 前立腺癌の診断および処置におけるマーカーの使用 | |
| US12448654B2 (en) | Compositions and methods for detecting pancreatic cancer | |
| CN102191320A (zh) | 用于诊断食管癌的组合物及方法 | |
| US20140030738A1 (en) | Soluble human m-csf receptor and uses thereof | |
| JP6092092B2 (ja) | 腎機能障害、糸球体濾過速度、呼吸困難、急性心不全、左心室肥大、心線維症、子癇前症、妊娠関連蛋白尿のバイオマーカーとしてのｌｔｂｐ２ | |
| JP2006510008A (ja) | アクチビンβＣのレベルの調節によって特徴付けられる状態のための診断方法、治療方法、および有用な薬剤 | |
| JP2006502203A (ja) | 筋肉損傷を監視し診断するための単離した翻訳後修飾タンパク質 | |
| CN111032053A (zh) | 靶向defa5抗体和用于诊断和治疗炎性肠病的测定方法 | |
| KR100884487B1 (ko) | 인자 ⅶ-활성화 프로테아제의 돌연변이체 및 특이적 항체를 포함하는 진단학적 조성물 | |
| CN108139404B (zh) | 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测 | |
| JP2003116549A (ja) | Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法 | |
| JP2002541214A5 (https=) | ||
| US9523690B2 (en) | Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
| WO2019242741A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
| JP2002510050A (ja) | 骨吸収速度を測定する方法 | |
| Houze et al. | Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer | |
| MX2008007881A (es) | Receptor m-csf humano soluble y usos del mismo | |
| US20120301879A1 (en) | Novel use of ca-125 | |
| CN103558391A (zh) | 可溶性人m-csf受体及其应用 | |
| JP2004085305A (ja) | 癌の診断方法 | |
| AU2012261609A9 (en) | Soluble human M-CSF receptor and uses thereof | |
| JP2008503718A (ja) | 良性前立腺過形成のマーカーとしてのｊｍ−２７ |